SEC Form 4 · accession 0000899243-18-025797
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adelene Q Perkins
Officer — Chief Executive Officer · Director
Period of report
Oct 1, 2018
Accepted (ET)
Oct 2, 2018 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Oct 1, 2018 | S | 5,000 | $2.82 | D | 609,561 | D | |
| Common Stock | holding | — | — | — | 16,447 | I | 401(K) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017.
- F2The price reported in this line of Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.80 to $2.88, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.
- F3Includes 7,309 shares of common stock acquired by Ms. Perkins on June 16, 2018 through participation in the issuer's Employee Stock Purchase Plan.